Theratechnologies Discusses Recent Financial Performance
MONTREAL — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a prominent biopharmaceutical company, recently revealed its financial results for the second quarter of fiscal 2025, ending on May 31, 2025. With total revenue reported at $17.7 million for the second quarter and $36.8 million for the first half of the fiscal year, the company is clearly navigating through a transformative period marked by strategic milestones.
Key Highlights from Q2 2025
During this quarter, Theratechnologies achieved notable accomplishments, including:
- Positive Adjusted EBITDA for the fifth consecutive quarter.
- Strong patient demand for EGRIFTA SV, resulting in high enrollment levels, despite earlier supply disruptions.
- A landmark agreement for acquisition by an affiliate of Future Pak, signaling significant growth potential.
President and CEO Paul Lévesque shared that the demand for EGRIFTA SV remains robust, citing record enrollments over the past months. This comes even as the company faced a supply shortage earlier in the fiscal year, which has since been resolved, leading to a notable uptick in unique patient figures and new enrollments.
A Future-Focused Strategy
As Theratechnologies sets sights on launching a new and improved version of EGRIFTA, specifically EGRIFTA WR™, the company plans to leverage the momentum built in the prior year. Lévesque emphasizes that the overall financial trajectory is steadily improving across both revenue and profit margins as the business gears up for continued growth.
Financial Guidance Adjustments
With the agreement to be acquired by Future Pak, Theratechnologies has withdrawn its fiscal 2025 revenue and EBITDA guidance. This strategic pivot aims to allow the company to adapt amidst this acquisition transition while focusing on organic growth drivers and product launches.
Summary of Financial Results
In terms of overall financial performance, Theratechnologies reported consolidated revenue of $17.7 million for Q2 2025, a decrease from $22 million in the same period last year, reflecting a year-over-year decline of 19.5%. The first half of the fiscal year mirrored this trend, landing revenue at $36.8 million, down 3.9% from $38.3 million the previous year.
Quarterly Sales Breakdown
Sales of EGRIFTA SV were $11.1 million, down from $16.2 million, driven primarily by lower unit sales attributed to market supply disruptions. Conversely, Trogarzo® saw an increase in sales to $6.6 million, up 13.4% from $5.8 million, showcasing recovery and stability in that segment.
Investments in Research & Development
Research and development (R&D) expenses during this quarter totaled $2.6 million, a decrease compared to the prior year. This easing of R&D expenditures aligns with the company's operational revisions regarding oncology and related drug development.
Company's Financial Outlook and Strategic Intent
The financial position of Theratechnologies reflects a strong liquidity stance with sufficient cash reserves to sustain operations, even as it plans for the future. The total cash balance stands at $9.5 million, showcasing the company's ability to navigate through transitional phases securely.
Looking Ahead
As Timothy Crook, Chief Financial Officer of Theratechnologies indicated, the expectation is to maintain operational expenditures effectively while growing revenues with a successful launch of EGRIFTA WR™. Monitoring the integration processes with Future Pak remains a priority, as this could usher in an expanded capacity for therapeutics, ultimately reinforcing Theratechnologies' market position.
Frequently Asked Questions
What are the recent financial results for Theratechnologies?
In Q2 2025, Theratechnologies reported a revenue of $17.7 million, down from $22 million in Q2 2024.
How is Theratechnologies planning to grow after the acquisition?
Post-acquisition, Theratechnologies aims to launch EGRIFTA WR™, build on enrollment momentum, and stabilize product lines.
What adjustments have been made to financial guidance?
Following their acquisition agreement, Theratechnologies has withdrawn their fiscal 2025 revenue and Adjusted EBITDA guidance.
What are the R&D spending trends observed?
R&D expenses have decreased to $2.6 million due to shifts away from oncology-related projects.
What is their current cash position?
As of now, Theratechnologies holds cash reserves amounting to $9.5 million, ensuring liquidity for operational needs.
